Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer's Hernexeos

July 16, 2026 11:18 AM EDT News Briefing Kelun pads ef­fi­ca­cy pro­file of Mer­ck-part­nered ADC; Eu­rope will have to wait for Boehringer's Hernex­eos ENDPOINTS Plus, news about Vo­genx and Orakl On­col­o­gy. 🇨🇳 Kelun touts Chi­na da­ta for sac-TMT: Kelun-Biotech an­nounced on Tues­day that its Mer­ck-part­nered an­ti­body-drug con­ju­gate sac­i­tuzum­ab tiru­mote­can … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER